Towards Healthcare

Microfluidics Manufacturers Technological Advancements, Revenue Diversification, Patent Expansions, Cross-border Expansion, Performance Gap Identification, Organizational Growth Plans, Operational Excellence

Date : 27 January 2025

Microfluidics Top Companies and Strategic Involvements

The global microfluidics market size was estimated at US$ 31.80 billion in 2023 and is projected to grow to US$ 103.06 billion by 2033, rising at a compound annual growth rate (CAGR) of 12.50% from 2024 to 2033.

Top Companies in the Microfluidics Market

  • Abbott
  • RedShiftBio
  • Takara Bio Inc.
  • Agilent Technologies, Inc.
  • Standard BioTools
  • PerkinElmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific
  • Danaher Corporation
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.

Recent Development by Takara Bio Inc. in the Microfluidics Market

Company Name Takara Bio Inc.
Headquarters Shiga, Japan, Asia Pacific
Recent Development In May 2024, the first dissolvable microfluidic transduction enhancer on the market, the Lenti-X Transduction Sponge, is a first for in vitro lentivirus-mediated gene delivery methods. It was unveiled today by Takara Bio U.S., Inc., a fully-owned subsidiary of Takara Bio Inc. The Lenti-X Transduction Sponge attains high transduction efficiency in any cell type with a simple, walkaway approach, opening up new research opportunities in the field of gene and cell therapy.

Recent Development by RedShiftBio in the Microfluidics Market

Company Name RedShiftBio
Headquarters Massachusetts, U.S., North America
Recent Development In May 2024, at the Protein & Antibody Engineering Summit (PEGS) in Boston, Massachusetts, RedShiftBio, a pioneer in cutting-edge biophysical characterization and bioprocess analytical solutions, announced the introduction of Aurora, TX. The company's most recent and sophisticated instrument, the Aurora TX, sets a new benchmark in biomolecular analysis with its groundbreaking microfluidic modulation spectroscopy technology and ultra-sensitive, ultra-precise measurements of biomolecule stability and structure. This instrument is now even more enhanced with the addition of thermal ramping capability.

Recent Developments in the Microfluidics Market

  • In May 2024, scientists at the National Institute of Standards and Technology (NIST) created bioelectronic instruments that can analyze cell activities in real-time. Researchers are including these elements in their adaptation of the heart-on-a-chip (HoC) system. With a heavy reliance on animal testing, traditional cardiovascular medication research has several shortcomings that this approach aims to solve. The Human Cardiac Model (HoC) has the potential to expedite drug development and save costs by substituting animal research with a more realistic model of the human body, which may capture important characteristics of the human cardiovascular system in a lab setting.
  • In April 2024, Boston Micro Fabrication (BMF) is pleased to announce the establishment of BMF Biotechnology Inc. to further facilitate the application of extremely accurate microfluidic solutions in advanced drug development, pharmaceutical, and cosmetic research. BMF Biotechnology Inc., a California company with its headquarters in San Diego, is committed to creating and marketing cutting-edge BioChips—organs-on-a-chip platforms—by growing large-scale tissues in vitro and accelerating the development of novel drugs and cosmetics.
  • In March 2023, in droplet microfluidic applications, a novel technique utilizing on-chip fiber optics allows for multiplexed fluorescence and scatter detection with previously unheard-of single-cell precision, according to a paper published in the journal Microsystems & Nanoengineering.
  • In May 2023, researchers at the University of Birmingham established a route towards 3D-bioprinted microfluidic tissues, organs, and arteries. By employing 3D bioprinting, research from the University of Birmingham may be able to shorten the lengthy waiting lists for organ transplants. The group claims that its research will hasten the implementation of microfluidic-based tissue in collaboration with collaborators at the University of Huddersfield and the Polytechnic University of Milan.
Date Description Port of Loading Port of Discharge Weight Quantity
Dec-17-2023 MICROFLUIDIZER MACHINE ANVERS NEW YORK/NEWARK AREA, NEWARK, NJ 1,200 1 CRT
Nov-13-2022 MICROFLUIDICS WORKSTATION PUSAN NEW YORK/NEWARK AREA, NEWARK, NJ 200 1 PKG
Sep-29-2021 1 PKG OF USED MICROFLUIDICS M 110P +INV NO.:P210830-1 +HS CODE:9027.90 PUSAN TACOMA, WA 161 1 PKG
Sep-09-2021 MICROFLUIDIZER PROCESSOR 7250-30 ASCEPTIC AUTOMATED ALONGWITH STANDARD ACCESSORIES SL.NO.72500083 WITH ELECTRICAL PANEL WITH ACCESSORIES JAWAHARLAL NEHRU NEW YORK/NEWARK AREA, NEWARK, NJ 2,410 3 BOX
Apr-04-2017 M700 MICROFLUIDIZER HS CODE 8479 82 0080 ANVERS NEW YORK/NEWARK AREA, NEWARK, NJ 1,040 1 PKG

Yearly Data

Year
 Number of shipment TEU Weight (KGs)
2023 1 1 1,200
2022 2 2 400
2021 3 3 4,981
2017 2 2 2,080